Fig. 3: Silence of PVT1 alleviated mitochondrial dysfunction and inflammation in high glucose-stimulated podocytes.
From: LncRNA PVT1 induces mitochondrial dysfunction of podocytes via TRIM56 in diabetic kidney disease
A The RNA levels of PVT1 in podocytes under different conditions (n = 5). B Measurement of the mitochondrial OCR of podocytes under different conditions (n = 5). C Energy phenotype profile (EPP) was mentioned. D Production of mtROS in podocytes (n = 5). Scale bar = 50 μm. E Representative fluorescence images of MitoTracker in podocytes cultured under the indicated conditions (n = 4). Scale bar =50 μm. F qRT-PCR measurement of the mRNA levels of BAX in podocytes (n = 5) and levels of mtDNA in cytoplasm of podocytes (n = 4). G Representative fluorescence images of podocytes with anti-Tom 20 (red) and anti-dsDNA (green) antibodies (n = 4). Scale bar = 50 μm. H Expression of TFAM, BAX, and mitochondrial OXPHOS proteins in podocytes under different conditions by western blotting (n = 4). I Expression of p-p65, p65, IL-6, TNF-α, and CXCL10 in podocytes under different conditions. J Representative fluorescence images of podocytes with anti-p65 antibody (n = 3). Scale bar = 50 μm. K Expression of p-p65, p65, IL-6, and TNF-α in podocytes in the presence of EtBr (1.0 μg/ml) to block the replication of mtDNA (n = 4). Error bars represent the mean± S.D, *P < 0.05, **P < 0.01, and ***P < 0.001.
